Impact of a modified peritoneal cancer index using FDG-PET/CT (PET-PCI) in predicting tumor grade and progression-free survival in patients with pseudomyxoma peritonei

2019 ◽  
Vol 29 (10) ◽  
pp. 5709-5716 ◽  
Author(s):  
Masatoshi Hotta ◽  
Ryogo Minamimoto ◽  
Yoshimasa Gohda ◽  
Toru Igari ◽  
Hideaki Yano
Keyword(s):  
Pseudomyxoma Peritonei ◽  
Fdg Pet ◽  
Peritoneal Cancer Index ◽  
Progression Free Survival ◽  
Tumor Grade ◽  
Free Survival ◽  
Peritoneal Cancer ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Positron Emission Tomography for the Response Evaluation following Treatment with Chemotherapy in Patients Affected by Colorectal Liver Metastases: A Selected Review

2015 ◽  
Vol 2015 ◽  
pp. 1-7 ◽  
Author(s):  
Alberto Zaniboni ◽  
Giordano Savelli ◽  
Claudio Pizzocaro ◽  
Pietro Basile ◽  
Valentina Massetti
Keyword(s):  
Liver Metastases ◽  
Fdg Pet ◽  
Therapy Response ◽  
Progression Free Survival ◽  
Free Survival ◽  
Positron Emission ◽  
Response To Chemotherapy ◽  
Pet Ct ◽  
Fdg Pet Ct ◽  
Ct And Mri

The aim of the present paper is to review the scientific literature concerning the usefulness of18F-FDG PET/CT in the evaluation of response to chemotherapy in patients affected by liver metastases from colorectal cancer.Material and Methods. Studies were identified by searching PubMed electronic databases. Both prospective and retrospective studies were included. Information regarding the figure of merit of PET for the evaluation of therapy response was extracted and analyzed.Results. Existing data suggests that18F-FDG PET/CT may have an outstanding role in evaluating the response. The sensitivity of PET in detecting therapy response seems to be greater than conventional imaging (CT and MRI). PET/CT response is strictly related to better overall survival and progression-free survival.Conclusions. PET/CT is more than a promising technique to assess the response to chemotherapy in colorectal and liver metastases. However, to be fully validated, this examination needs further studies by recruiting more patients.

FDG-PET/CT is Predictive of Progression-free Survival in Anal Cancer

2009 ◽  
Vol 75 (3) ◽  
pp. S258-S259
Author(s):  
W.W. Lien ◽  
A.R. Rao ◽  
J.S. Kaptein ◽  
M.A. Tome
Keyword(s):  
Anal Cancer ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
Fdg Pet Ct

scholarly journals Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival

2021 ◽  
Vol 20 ◽  
pp. 153303382110564
Author(s):  
Na Dai ◽  
Hang Liu ◽  
Shengming Deng ◽  
Shibiao Sang ◽  
Yiwei Wu
Keyword(s):  
Prognostic Factor ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Lymphoblastic Lymphoma ◽  
Emission Tomography ◽  
Free Survival ◽  
Positron Emission ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

Purpose: In the present study, we mainly aimed to evaluate the prognostic value of 2-deoxy-2-[18F]fluoro-D-glucose ([18F]F-FDG) positron emission tomography (PET)/computed tomography (CT) after allogeneic stem cell transplantation (allo-SCT) in lymphoblastic lymphoma (LBL) patients using Deauville Scores (DS). Materials and Methods: A total of 63 LBL patients who benefited from 18F-FDG PET-CT after allo-SCT in our institution between April 2010 and August 2020 were enrolled in this retrospective study. These above-mentioned patients were divided into two groups based on the Deauville criteria. Diagnostic efficiency of 18F-FDG PET/CT and integrated CT in detecting lymphoma were calculated. Consistencies were evaluated by comparing 18F-FDG PET/CT and integrated CT results through kappa coefficient. Kaplan-Meier method was used in survival analysis, and the log-rank method was adopted in comparisons. Prognostic factor analysis was performed by the Cox regression model. Results: The sensitivity, specificity, positive predictive value, negative predictive value, accuracy of post-SCT 18F-FDG PET-CT were 100%(12/12), 92.2%(47/51), 75.0%(12/16), 100%(47/47) and 93.7%(59/63). The consistency of 18F-FDG PET-CT and integrated CT was moderate(Kappa = .702，P < .001). Positive post-SCT 18F-FDG PET-CT was associated with lower progression-free survival (PFS) but not overall survival (OS) (p = .000 and p = .056, respectively). The 3-year PFS of the PET-positive group and PET-negative group was 18.8% and 70.2%, respectively. Multivariate analysis showed that post-SCT PET-CT findings was an independent prognostic factor for PFS (p = .000; HR, 3.957; 95%CI, 1.839-8.514). Other factors independently affecting PFS were sex (p = .018; HR, 2.588; 95% CI, 1.181 − 5.670) and lactate dehydrogenase (LDH) (p = .005; HR, 3.246; 95% CI, 1.419 − 7.426). However, none of the above-mentioned factors were associated with OS. Conclusions: Collectively, we found that 18F-FDG PET-CT after allo-SCT was a strong indicator for PFS, but not OS, which might provide important evidence for the selection of subsequent treatment regimen for LBL patients. Trial registration number: ChiCTR2100046709.

Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET

2020 ◽  
Vol 129 ◽  
pp. 109076
Author(s):  
Dragana P. Sobic Saranovic ◽  
Marina Nikitovic ◽  
Jelena Saponjski ◽  
Isidora Grozdic Milojevic ◽  
Lejla Paripovic ◽  
...  
Keyword(s):  
Ewing Sarcoma ◽  
Fdg Pet ◽  
Young Patients ◽  
Progression Free Survival ◽  
Post Treatment ◽  
Free Survival ◽  
Pet Ct ◽  
Blue Cell ◽  
Fdg Pet Ct

scholarly journals [18F]FDG PET/CT predicts progression-free survival in patients with idiopathic pulmonary fibrosis

2017 ◽  
Vol 18 (1) ◽  
Author(s):  
Aurélien Justet ◽  
Astrid Laurent-Bellue ◽  
Gabriel Thabut ◽  
Arnaud Dieudonné ◽  
Marie-Pierre Debray ◽  
...  
Keyword(s):  
Idiopathic Pulmonary Fibrosis ◽  
Pulmonary Fibrosis ◽  
Fdg Pet ◽  
Progression Free Survival ◽  
Free Survival ◽  
Pet Ct ◽  
18F Fdg ◽  
Fdg Pet Ct

ATL: Does Metabolic Response Predicts Survival?

2014 ◽  
Vol 24 (2) ◽  
pp. 312-320 ◽  
Author(s):  
Varun Singh Dhull ◽  
Punit Sharma ◽  
Daya Nand Sharma ◽  
Sagar Maharjan ◽  
Sudhir Suman KC ◽  
...  
Keyword(s):  
Fdg Pet ◽  
Metabolic Response ◽  
Progression Free Survival ◽  
Response Evaluation ◽  
Carcinoma Cervix ◽  
Free Survival ◽  
Treatment Response Evaluation ◽  
Positron Emission ◽  
Pet Ct ◽  
Fdg Pet Ct

PurposeThis study aimed to assess the role of18F-fluorodeoxyglucose positron emission tomography–computed tomography (18F-FDG PET-CT) in response assessment of patients with recurrent carcinoma cervix and in evaluating the predictive value of metabolic response for progression-free survival (PFS) and overall survival (OS).MethodsThirty-six patients with histopathologically or clinically evident recurrent cervical carcinoma underwent a pretherapy and a posttherapy18F-FDG PET-CT for treatment response evaluation. Positron emission tomography–CT images were analyzed by 2 experienced nuclear medicine physicians. Response was categorized using European Organization for Research and Treatment of Cancer (EORTC) criteria into complete metabolic response (CMR), partial metabolic response (PMR), stable metabolic disease (SMD), and progressive metabolic disease (PMD). Clinical/imaging follow-up (minimum of 6 months) and/or histopathologic findings were taken as reference standard. Patients were categorized into 2 groups, those with PMD and those without PMD (ie, CMR, PMR, and SMD). Progression-free survival and OS based on PET-CT response were measured from the date of posttherapy PET-CT to the first documentation of progression of disease and death, respectively.ResultsOn the basis of metabolic response on posttherapy PET-CT, 6 patients had CMR, 12 patients had PMR, 7 patients had SMD, and 11 patients had PMD. Progression-free survival for patients with cervical carcinoma ranged from 0.5 to 26.5 months (mean [SD], 6.7 [6.1] months). Median PFS for patients with PMD was 3.1 months, whereas median PFS for those without PMD was not reached. Patients who did not show PMD on posttherapy PET-CT had a significantly better PFS than those patients who showed PMD (P< 0.0001; HR, 0.14). There was no statistically significant difference in OS between the 2 groups (P= 0.187; HR, 0.39).Conclusions18F-fluorodeoxyglucose PET-CT is an effective tool for treatment response evaluation in recurrent carcinoma cervix. Patients with metabolically progressive disease on posttherapy18F-FDG PET-CT have a significantly shorter PFS.

Sign in / Sign up

Export Citation Format

Share Document